SAN DIEGO — Danish microRNA firm Exiqon this week detailed its plans to enter the molecular diagnostics market by the end of the year with a microRNA-screening assay for colorectal cancer recurrence.
The move comes a week after the company changed the name of its clinical laboratory diagnostics subsidiary from Oncotech to Exiqon Diagnostics.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
